BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38042707)

  • 1. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
    Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
    Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation.
    Eger K; Kroes JA; Ten Brinke A; Bel EH
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1194-1200. PubMed ID: 33069885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
    Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
    J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice].
    Fomina DS; Mukhina OA; Lebedkina MS; Gadzhieva MK; Bobrikova EN; Sinyavkin DO; Parshin VV; Chernov AA; Belevskiy AS
    Ter Arkh; 2022 Mar; 94(3):413-419. PubMed ID: 36286907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
    Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort.
    Milger K; Suhling H; Skowasch D; Holtdirk A; Kneidinger N; Behr J; Timmermann H; Schulz C; Schmidt O; Ehmann R; Hamelmann E; Idzko M; Taube C; Lommatzsch M; Buhl R; Korn S
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2701-2712.e2. PubMed ID: 37301433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IL5 therapies for asthma.
    Farne HA; Wilson A; Powell C; Bax L; Milan SJ
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
    Thomas D; McDonald VM; Stevens S; Harvey ES; Baraket M; Bardin P; Bowden JJ; Bowler S; Chien J; Chung LP; Gillman A; Hew M; Hodge S; James A; Jenkins C; Katelaris CH; Katsoulotos GP; Langton D; Lee J; Marks G; Peters M; Radhakrishna N; Reynolds PN; Rimmer J; Sivakumaran P; Upham JW; Wark P; Yang IA; Gibson PG
    Allergy; 2024 Feb; 79(2):384-392. PubMed ID: 37632144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-5 therapies for asthma.
    Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    J Asthma; 2023 Oct; 60(10):1862-1868. PubMed ID: 36971065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
    Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
    Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy.
    Nagase H; Suzukawa M; Oishi K; Matsunaga K
    Allergol Int; 2023 Jan; 72(1):11-23. PubMed ID: 36543689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both.
    Pfeffer PE; Ali N; Murray R; Ulrik C; Tran TN; Maspero J; Peters M; Christoff GC; Sadatsafavi M; Torres-Duque CA; Altraja A; Lehtimäki L; Papadopoulos NG; Salvi S; Costello RW; Cushen B; Heffler E; Iwanaga T; Al-Ahmad M; Larenas-Linnemann D; Kuna P; Fonseca JA; Al-Lehebi R; Rhee CK; Perez-de-Llano L; Perng Steve DW; Mahboub B; Wang E; Goh C; Lyu J; Newell A; Alacqua M; Belevskiy AS; Bhutani M; Bjermer L; Bjornsdottir U; Bourdin A; Bulow AV; Busby J; Canonica GW; Cosio BG; Dorscheid DR; Muñoz-Esquerre M; FitzGerald JM; Gil EG; Gibson PG; Heaney LG; Hew M; Hilberg O; Hoyte F; Jackson DJ; Koh MS; Ko HB; Lee JH; Lehmann S; Chaves Loureiro C; Lúðvíksdóttir D; Menzies-Gow AN; Mitchell P; Papaioannou AI; Popov TA; Porsbjerg CM; Salameh L; Sirena C; Taillé C; Taube C; Tohda Y; Wechsler ME; Price DB
    Allergy; 2023 Jul; 78(7):1934-1948. PubMed ID: 36929509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.